Abstract
Chemoradiotherapy (CRT) is the latest modality to be explored as a treatment for gastric cancer. Advances have been made in the United States with CRT as preoperative or postoperative adjuvant treatment. The rationale for preoperative or postoperative adjuvant CRT is to increase the curability of surgery or to prevent local recurrence, because standard surgery (D0 or D1) is not sufficient to control local relapse and improve survival where disease has become advanced. D2 is standard in Japan and D2 gastrectomy plus postoperative adjuvant chemotherapy with S-1 is currently standard for stage II and III cancer. Predominant recurrence patterns associated with these advanced disease stages are peritoneal dissemination and hematogenous metastasis. Local relapse or regional nodal recurrence is infrequent. CRT has been provided at only a limited number of institutions in Japan. The response to and safety of CRT for gastric cancer, in combination with various chemotherapeutic agents, are currently being studied in patients with unresectable or recurrent disease. Considering the high response rate, CRT seems to be an attractive option. In the near future, an examination will be made to ascertain whether neoadjuvant CRT in combination with extensive surgery has survival benefits in the treatment of locally advanced disease. Prior to this, a phase I/II study should be conducted in patients with unresectable or recurrent disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Moertel CG, Childs DS Jr, Reitemeier RJ, et al. (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet II:865–867
Schein P, Novak J (for GITSG) (1982) Combined modality therapy (XRT-chemo) versus chemotherapy alone for locally unresectable gastric cancer. Cancer Chemother Pharmacol 49:1771
Macdonald JS, Smalley SR, Benedetti J, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730
Ajani JA, Mansfield PF, Janjan N, et al. (2004) Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 22:2774–2780
Ajani JA, Mansfield PF, Crane CH, et al. (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237–1244
Ajani JA, Winter K, Okawara GS, et al. (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 24:3953–3958
Ng K, Meyerhardt JA, Fuchs C (2007) Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J 13:168–174
Abe M, Takahashi M, Ono K, et al. (1988) Japan gastric trials in intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:1431–1433
Saikawa Y, Kiyota T, Nakamura R, et al. (2006) A recent trial of chemo-radiation with S-1 against gastric cancer. Jpn J Cancer Chemother 33(Suppl I):99–105
Bonenkamp JJ, Hermans J, Sasako M, et al. (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908–914
Wu C-W, Hsiung CA, Lo S-S, et al. (2006) Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol 7:309–315
Sasako M, Sano T, Yamamoto A, et al. (2006) Randomized phase III trial of standard D2 versus D2 + para-aortic lymph node (PAN) dissection (D) for clinically M0 advanced gastric cancer: JCOG 9501. J Clin Oncol 24: 18S (abstract #LBA4015)
Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Sakuramoto S, Sasako M, Yamaguchi T, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820
Kim S, Lim DH, Lee J, et al. (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279–1285
Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 25:18S (abstract # LBA4513)
Narahara H, Koizumi W, Hara T, et al. (2007) Randomized phase III study of S-1 + cisplatin in the treatment for advanced gastric cancer (the SPRITS trial) SPRITS: S-1 + cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol 25:18S (abstract #4514)
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tsujinaka, T., Fujitani, K., Hirao, M. et al. Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol 13, 117–120 (2008). https://doi.org/10.1007/s10147-007-0743-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-007-0743-1